Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

Vapreotide

Name: Vapreotide
Brand: TargetMol
SKU: T13306
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T13306Cas No. 103222-11-3

Alias RC160, BMY 41606

Vapreotide is an antagonist of the neurokinin-1 (NK1) receptor (IC50: 330 nM).

Vapreotide

Copy Product Info

😃Good

Catalog No. T13306Alias RC160, BMY 41606Cas No. 103222-11-3

Vapreotide is an antagonist of the neurokinin-1 (NK1) receptor (IC50: 330 nM).

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
50 mg	Inquiry	Inquiry	Inquiry
100 mg	Inquiry	Inquiry	Inquiry

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

Product Introduction

Bioactivity

Description	Vapreotide is an antagonist of the neurokinin-1 (NK1) receptor (IC50: 330 nM).
Targets&IC50	NK1R:330 nM
In vitro	In a concentration-dependent manner, Vapreotide attenuates the effect of SP on calcium release . The concentration required for Vapreotide to completely inhibit the effect of SP is about 100 times higher than that required for the NK1R antagonist aprepitant. The effect of Vapreotide on cell proliferation is mediated primarily by SSTR2. In order to further establish the NK1R antagonist effect of Vapreotide, U373MG cells are pretreated with SSTR2 selective antagonist CYN followed by incubation with Vapreotide and SP stimulation. The results show that pretreatment with CYN does not reverse the inhibitory effect of Vapreotide on SP-stimulated IL-8 mRNA expression. As compared to control MDM, limited HIV gag mRNA expression may indicate that Vapreotide can reduce HIV-1 replication in MDM. In addition, SP treatment (10 μM) reversed the inhibitory effect of pentoprofen on HIV-1 replication in MDM. This observation indicates that the inhibitory effect of Vapreotide on HIV-1 replication is most likely due to its interaction with NK1R.
Synonyms	RC160, BMY 41606

Chemical Properties

Molecular Weight	1131.38
Formula	C₅₇H₇₀N₁₂O₉S₂
Cas No.	103222-11-3
Smiles	[H][C@@]1(Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)C(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O)NC(=O)[C@H](N)Cc1ccccc1 \|@:49\|
Relative Density.	1.4 g/cm3
Sequence	{d-Phe}-Cys-Tyr-{d-Trp}-Lys-Val-Cys-Trp-NH2 (Disulfide bridge: Cys2-Cys7)
Sequence Short	{d-Phe}-CY-{d-Trp}-KVCW (Disulfide bridge: Cys2-Cys7)

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: 60 mg/mL (53.03 mM), Sonication is recommended.

Solution Preparation Table

H2O

	1mg	5mg	10mg	50mg
1 mM	0.8839 mL	4.4194 mL	8.8388 mL	44.1938 mL
5 mM	0.1768 mL	0.8839 mL	1.7678 mL	8.8388 mL
10 mM	0.0884 mL	0.4419 mL	0.8839 mL	4.4194 mL
20 mM	0.0442 mL	0.2210 mL	0.4419 mL	2.2097 mL
50 mM	0.0177 mL	0.0884 mL	0.1768 mL	0.8839 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc